Binder, Claudia

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","112"],["dc.bibliographiccitation.volume","80"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:23:01Z"],["dc.date.available","2018-11-07T09:23:01Z"],["dc.date.issued","2001"],["dc.description.abstract","Transplantation of peripheral blood stem cells (PBSC), positively and/or negatively selected immediately after harvest, has become a widely applied therapeutic option in hematological or oncological patients. The following case of peripheral blood stem cell transplantation represents the first case of successful transplantation of PBSC, cryopreserved twice and purged after cryopreservation. PBSC were harvested in a 44-year-old female patient with a low-grade non-Hodgkin's lymphoma stage IV after mobilization with chemotherapy and G-CSF. A total number of 15.2 x 10(6) CD34(+) cells/kg bodyweight was harvested with a 36.9% contamination of tumor cells coexpressing CD5 and CD20. After subsequent chemotherapy cycles and cyclophosphamide mobilization, only 0.77 x 10(6) CD34(+) cells/kg bodyweight, not sufficient for transplantation, were achieved after positive selection. Therefore, 10.8 x 10(6) cryopreserved CD34(+) cells/kg bodyweight were thawed and a positive selection was carried out with the BAXTER Isolex 300i machine. Before additional negative selection, the 0.77 x 10(6) positively selected CD34(+) cells/kg bodyweight from the second mobilization were added. A total quantity of 4.4 x 10(6) CD34(+) cells/kg bodyweight with a purity of 93.1% representing a recovery of 38% was obtained. Cells were again cryopreserved, stored and retransfused after conditioning the patient with TBI and high-dose cyclophosphamide. The patient engrafted with a WBC count >1000/mul on day eight and a platelet count > 20,000/mul without transfusion support on day 12 post-transplantation. This case indicates that purging procedures can successfully be carried out with cryopreserved cell material and that purified CD34(+) cells can be cryopreserved a second time before transplantation, without affecting their hematopoietic capacity."],["dc.identifier.doi","10.1007/s002770000243"],["dc.identifier.isi","000167191200010"],["dc.identifier.pmid","11261320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29482"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Successful transplantation and engraftment of peripheral blood stem cells after cryopreservation, positive and negative purging procedures, and a second cryopreservation cycle"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","285"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","286"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Menck, Kerstin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Scharf, Christian"],["dc.contributor.author","Pukrop, Tobias"],["dc.contributor.author","Dyck, Lydia"],["dc.contributor.author","Klemm, Florian"],["dc.contributor.author","Binder, Claudia"],["dc.date.accessioned","2018-11-07T09:34:18Z"],["dc.date.available","2018-11-07T09:34:18Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900702"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32144"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","EMMPRIN/CD147-positive tumor cell microvesicles are pro-invasive and detectable in the blood of cancer patients with metastasis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","98"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","103"],["dc.bibliographiccitation.volume","82"],["dc.contributor.author","Schuttrumpf, S."],["dc.contributor.author","Binder, L."],["dc.contributor.author","Hagemann, T."],["dc.contributor.author","Berkovic, D."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Binder, Claudia"],["dc.date.accessioned","2018-11-07T10:41:02Z"],["dc.date.available","2018-11-07T10:41:02Z"],["dc.date.issued","2003"],["dc.description.abstract","Plasma concentrations of procalcitonin (PCT) have been shown to be elevated in bacterial and fungal infections. In contrast to C-reactive protein (CRP), PCT is not elevated in inflammations of noninfectious origin. Febrile inflammatory conditions are frequent in patients with hemato-oncological diseases. A reliable marker to discriminate infectious inflammations from drug-related and tumor-associated fever is still lacking. To evaluate the impact of PCT in this setting, PCT and CRP were prospectively measured in 95 febrile hemato-oncological patients. Infections could be identified in 40 of 95 patients: 38 of 95 had fever of unknown origin (FUO), 9 patients were suspected to suffer from drug-related fever, and 8 patients from tumor-associated fever. In the noninfection group (drug-related and tumor-associated fever), PCT levels were significantly lower than in patients with infections (P<0.001) or FUO (P<0.001). Differences were still highly significant comparing patients with suspected drug-related or tumor-associated fever alone with the infection or the FUO cohort. All eight patients with tumor-associated fever as well as eight of the nine patients with drug-related fever had PCT levels within the normal range (<0.5 mu g/l). CRP values only partially allowed discrimination between the various subgroups. Differences were significant between patients with drug-related fever and the infection (P=0.001) or FUO group (P=0.004). However, as CRP levels were far above the normal range also in the patients with drug-related fever, the significance of individual values was rather limited. In conclusion, PCT may provide useful additional information to assess the clinical significance of febrile conditions. PCT may facilitate the decision on when to initiate antimicrobial or cytotoxic therapy."],["dc.identifier.doi","10.1007/s00277-002-0584-y"],["dc.identifier.isi","000181574600007"],["dc.identifier.pmid","12601488"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46448"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","459"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","462"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Tiemann, Markus"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Kneba, Michael"],["dc.date.accessioned","2018-11-07T10:34:30Z"],["dc.date.available","2018-11-07T10:34:30Z"],["dc.date.issued","2000"],["dc.description.abstract","Isolated chloromas (granulocytic sarcomas) are rare tumors, most of them progressing to acute myeloblastic leukemia within months. There are still no conclusive treatment strategies for this entity; however, early antileukemic chemotherapy seems to lower the probability of developing systemic disease and prolong survival. We report on a patient with isolated meningeal chloroma, primarily misdiagnosed as a high-grade Non-Hodgkin's lymphoma. Two cycles of antileukemic induction chemotherapy were administered, followed by local irradiation and intensified consolidation therapy with autologous stem cell transplantation. After 20 months, he is still in complete remission."],["dc.identifier.doi","10.1007/s002770000165"],["dc.identifier.isi","000088874900010"],["dc.identifier.pmid","10985368"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44886"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Isolated meningeal chloroma (granulocytic sarcoma) - a case report and review of the literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1521"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1528"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Duehrsen, Ulrich"],["dc.contributor.author","Eimermacher, Hartmut"],["dc.contributor.author","Aldaoud, A."],["dc.contributor.author","Rosenwald, Andreas"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:18:20Z"],["dc.date.available","2018-11-07T09:18:20Z"],["dc.date.issued","2013"],["dc.description.abstract","The rate of long-term remissions after treatment of peripheral T cell lymphomas (PTCL) with standard CHOP-like protocols is unsatisfactory. A prospective multicenter phase II trial was initiated in untreated patients with PTCL of all International Prognostic Index-risk groups, evaluating alemtuzumab consolidation in patients with complete or good partial remission after CHO(E)P-14 induction. Twenty-nine (70.7 %) of the 41 enrolled patients received alemtuzumab consolidation (133 mg in total). The main grades 3-4 toxicities during alemtuzumab therapy were infections and neutropenia with one potentially treatment-related death. Complete responses were seen in 58.5 %, partial responses in 2.4 % and 29.3 % had progressive disease. After a median observation time of 46 months, 19 patients have died, 16 of them due to lymphoma and/or salvage therapy complications. Event-free and overall survival at 3 years in the whole intent to treat population are 32.3 and 62.5 %, respectively, and 42.4 and 75.1 % in the patients who received alemtuzumab. In conclusion, application of a short course of alemtuzumab after CHO(E)P-14 induction is feasible although complicated by severe infections. A current phase III trial, applying alemtuzumab as part of the initial chemotherapy protocol to avoid early progression, will further clarify its significance for the therapeutic outcome."],["dc.identifier.doi","10.1007/s00277-013-1880-4"],["dc.identifier.isi","000325357600010"],["dc.identifier.pmid","23978945"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28389"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Siam, Laila"],["dc.contributor.author","Klemm, Florian"],["dc.contributor.author","Rietkoetter, Eva"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Stadelmann, Christine"],["dc.contributor.author","Pukrop, Tobias"],["dc.date.accessioned","2018-11-07T08:52:16Z"],["dc.date.available","2018-11-07T08:52:16Z"],["dc.date.issued","2011"],["dc.format.extent","151"],["dc.identifier.isi","000295160600393"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22130"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","LEF1 identifies a prognostically unfavourable subgroup of lung adenocarcinoma brain metastases"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","293"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","LaboratoriumsMedizin"],["dc.bibliographiccitation.lastpage","302"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Oellerich, Michael"],["dc.date.accessioned","2018-11-07T11:25:10Z"],["dc.date.available","2018-11-07T11:25:10Z"],["dc.date.issued","2009"],["dc.description.abstract","The selective estrogen receptor modulator tamoxifen is approved for treatment of hormone receptor-positive breast cancer in pre- and postmenopausal patients. The main active metabolite of tamoxifen is endoxifen, which has high affinity towards the receptor and reaches high plasma concentrations. Endoxifen results from cytochrome P450 enzyme CYP2D6 action. CYP2D6 is subject to genetic polymorphism, with a prevalence of enzyme deficiency of approximately 7% in most European populations. Enzyme deficiency is reliably predicted by genotyping of known CYP2D6 deficiency alleles. Poor metabolizers (homozygote carriers of deficiency alleles) exhibit lower endoxifen plasma concentrations. Retrospective analyses of tamoxifen study data according to CYP2D6 genotypes reveal a poorer oncological outcome for subjects with deficiency alleles in most studies (level 3 evidence). Data from randomized controlled studies (level 1 evidence) on the use of CYP2D6 typing for tamoxifen therapy are lacking. However, CYP2D6 genotyping before initiating tamoxifen therapy and avoidance of tamoxifen in postmenopausal women with a CYP2D6 enzyme deficiency seem warranted. Prescribing information does not list CYP2D6 status as a contraindication for tamoxifen. Pharmacological supression of hot flashes by comedication with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) must be avoided because such patients will become functional Poor metabolizers with lower endoxifen levels."],["dc.identifier.doi","10.1515/JLM.2009.048"],["dc.identifier.isi","000270609700007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56569"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Walter De Gruyter & Co"],["dc.relation.issn","0342-3026"],["dc.title","CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Hartmann, Joerg Thomas"],["dc.contributor.author","Metzner, Bernd"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Mergenthaler, Hans-Guenther"],["dc.contributor.author","Rick, Oliver"],["dc.contributor.author","Sayer, Herbert G."],["dc.contributor.author","Lorch, Anja"],["dc.contributor.author","Berdel, Wolfgang E."],["dc.contributor.author","Bokemeyer, Carsten"],["dc.contributor.author","Gauler, Thomas C."],["dc.date.accessioned","2018-11-07T09:06:13Z"],["dc.date.available","2018-11-07T09:06:13Z"],["dc.date.issued","2012"],["dc.format.extent","284"],["dc.identifier.isi","000309409001340"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25504"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","37th Congress of the European-Society-for-Medical-Oncology (ESMO)"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","0923-7534"],["dc.title","ADDITION OF DARBEPOETIN ALFA TO SEQUENTIAL HIGH DOSE VIP CHEMOTHERAPY FOR PATIENTS WITH ADVANCED METASTATIC GERM CELL CANCER"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","UNSP e50881"],["dc.bibliographiccitation.issue","80"],["dc.bibliographiccitation.journal","Journal of Visualized Experiments"],["dc.contributor.author","Chuang, Han-Ning"],["dc.contributor.author","Lohaus, Raphaela"],["dc.contributor.author","Hanisch, Uwe-Karsten"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Dehghani, Faramarz"],["dc.contributor.author","Pukrop, Tobias"],["dc.date.accessioned","2018-11-07T09:19:40Z"],["dc.date.available","2018-11-07T09:19:40Z"],["dc.date.issued","2013"],["dc.description.abstract","Patients with cerebral metastasis of carcinomas have a poor prognosis. However, the process at the metastatic site has barely been investigated, in particular the role of the resident (stromal) cells. Studies in primary carcinomas demonstrate the influence of the microenvironment on metastasis, even on prognosis(1,2). Especially the tumor associated macrophages (TAM) support migration, invasion and proliferation(3). Interestingly, the major target sites of metastasis possess tissue-specific macrophages, such as Kupffer cells in the liver or microglia in the CNS. Moreover, the metastatic sites also possess other tissue-specific cells, like astrocytes. Recently, astrocytes were demonstrated to foster proliferation and persistence of cancer cells(4,5). Therefore, functions of these tissue-specific cell types seem to be very important in the process of brain metastasis(6,7). Despite these observations, however, up to now there is no suitable in vivo/in vitro model available to directly visualize glial reactions during cerebral metastasis formation, in particular by bright field microscopy. Recent in vivo live imaging of carcinoma cells demonstrated their cerebral colonization behavior(8). However, this method is very laborious, costly and technically complex. In addition, these kinds of animal experiments are restricted to small series and come with a substantial stress for the animals (by implantation of the glass plate, injection of tumor cells, repetitive anaesthesia and long-term fixation). Furthermore, in vivo imaging is thus far limited to the visualization of the carcinoma cells, whereas interactions with resident cells have not yet been illustrated. Finally, investigations of human carcinoma cells within immunocompetent animals are impossible(8). For these reasons, we established a coculture system consisting of an organotypic mouse brain slice and epithelial cells embedded in matrigel (3D cell sphere). The 3D carcinoma cell spheres were placed directly next to the brain slice edge in order to investigate the invasion of the neighboring brain tissue. This enables us to visualize morphological changes and interactions between the glial cells and carcinoma cells by fluorescence and even by bright field microscopy. After the coculture experiment, the brain tissue or the 3D cell spheroids can be collected and used for further molecular analyses (e.g. qRT-PCR, IHC, or immunoblot) as well as for investigations by confocal microscopy. This method can be applied to monitor the events within a living brain tissue for days without deleterious effects to the brain slices. The model also allows selective suppression and replacement of resident cells by cells from a donor tissue to determine the distinct impact of a given genotype. Finally, the coculture model is a practicable alternative to in vivo approaches when testing targeted pharmacological manipulations."],["dc.identifier.doi","10.3791/50881"],["dc.identifier.isi","000209228800045"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28693"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Journal Of Visualized Experiments"],["dc.relation.issn","1940-087X"],["dc.title","Coculture System with an Organotypic Brain Slice and 3D Spheroid of Carcinoma Cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1363"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","1370"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Kurz, M."],["dc.contributor.author","Eil, A."],["dc.contributor.author","Storkebaum, B."],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Funke, I."],["dc.contributor.author","Hocker, P."],["dc.contributor.author","Wiesneth, M."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T08:55:02Z"],["dc.date.available","2018-11-07T08:55:02Z"],["dc.date.issued","2000"],["dc.description.abstract","BACKGROUND: Mobilization and homing of PBPCs are still poorly understood. Thus, a sufficient algorithm for the prediction of PBPC yield in apheresis procedures does not yet exist. STUDY DESIGN AND METHODS: The decline of CD34+ cells in the peripheral blood during apheresis and their simultaneous increase in the collection bag were determined in a prospective study of 18 consecutive apheresis procedures. A cell-kinetic, four-compartment model describing these changes was developed. Retrospective data from 136 apheresis procedures served to further improve this model. A predictive algorithm for the yield was developed that considered the sex, weight, and height of the patient, the number of CD34+ cells in peripheral blood before apheresis, the inlet flow, and the duration of the apheresis. The accuracy of this algorithm was evaluated by comparison of the predicted and the observed yields of CD34+ cells in 105 prospective autologous and 148 retrospective allogeneic apheresis procedures. RESULTS: The correlation between predicted and observed yields was good for the autologous and allogeneic groups with a correlation coefficient (r) of 0.8979 and 0.8311 (p<0.0001), respectively. The regression is described by the equations log (measured value [m]) = 1.0118 + 0.8595 x log (predicted value [p]) for the autologous and log (m) = 2.226 + 0.7559 x log (p) for the allogeneic group. The respective equations for the zero-point regression are log (m)= 1.014 x log (p) and log (m) = 1.026 x log (p). The probability that the measured value was 90 percent or more of the predicted value was 83.8 percent for the autologous and 90.5 percent for the allogeneic apheresis procedures. CONCLUSION: The predictive accuracy of the algorithm and the slope of the zero-point regression curve were higher for allogeneic than autologous PBPC collections. The predictive algorithm may be a useful tool in PBPC harvest, enabling the adaptation of the size of the apheresis to the needs of each patient."],["dc.identifier.doi","10.1046/j.1537-2995.2000.40111363.x"],["dc.identifier.isi","000165492600013"],["dc.identifier.pmid","11099666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22808"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","A cell-kinetic model of CD34+cell mobilization and harvest: development of a predictive algorithm for CD34+cell yield in PBPC collections"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]